Cargando…

Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapy

Detalles Bibliográficos
Autores principales:	Popovic, Relja, Dunbar, Fengjiao, Lu, Charles, Robinson, Kenneth, Quarless, Danjuma, Warder, Scott E., Mukherjee, Nabanita, Pesko, John, Souers, Andrew J., Waring, Jeffrey F., Davids, Matthew S., Tausch, Eugen, Stilgenbauer, Stephan, Ross, Jeremy A., Leverson, Joel D., Kim, Su Young, Chyla, Brenda J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Correspondences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10015991/ https://www.ncbi.nlm.nih.gov/pubmed/34779028 http://dx.doi.org/10.1002/ajh.26411

Ejemplares similares

Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia
por: Chyla, Brenda, et al.
Publicado: (2018)

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
por: Handunnetti, Sasanka, et al.
Publicado: (2021)

Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax
por: Ackler, Scott, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2015)

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)
por: Phillips, D C, et al.
Publicado: (2016)

Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination
por: Lew, Thomas E., et al.
Publicado: (2022)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Therapeutics Targeting the Core Apoptotic Machinery
por: Hamilton, Claudia, et al.
Publicado: (2021)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells
por: Bodo, Juraj, et al.
Publicado: (2016)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia
por: Zhou, Cheng, et al.
Publicado: (2022)

Potential mechanisms of resistance to venetoclax and strategies to circumvent it
por: Tahir, Stephen K., et al.
Publicado: (2017)

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma
por: Zhao, Xiaoxian, et al.
Publicado: (2020)

Durable Response to Venetoclax Monotherapy in Richter’s Syndrome: A Case Report and Review of Literature
por: Kollipara, Revathi, et al.
Publicado: (2019)

Profile of venetoclax and its potential in the context of treatment of relapsed or refractory chronic lymphocytic leukemia
por: Huber, Henriette, et al.
Publicado: (2017)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Case report: Successful treatment of refractory immune thrombocytopenia in chronic lymphocytic leukaemia with venetoclax monotherapy
por: Woo, Timothy, et al.
Publicado: (2023)

Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes
por: Gomez-Bougie, Patricia, et al.
Publicado: (2013)

Engulfment signals and the phagocytic machinery for apoptotic cell clearance
por: Park, Seung-Yoon, et al.
Publicado: (2017)

Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study
por: Wei, Andrew H., et al.
Publicado: (2019)

Relationship Between Venetoclax Exposure and Undetectable Minimal Residual Disease Rates in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of Six Clinical Studies
por: Gopalakrishnan, Sathej, et al.
Publicado: (2023)

Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis
por: Lovato, Ester, et al.
Publicado: (2023)

Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells
por: Ludwig, Lindsey M., et al.
Publicado: (2021)

Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study
por: Davids, Matthew S., et al.
Publicado: (2021)

Durable remissions with venetoclax monotherapy in secondary AML refractory to hypomethylating agents and high expression of BCL‐2 and/or BIM
por: Huemer, Florian, et al.
Publicado: (2019)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
por: Lim, Byungho, et al.
Publicado: (2022)

Venetoclax with decitabine versus decitabine monotherapy in elderly acute myeloid leukemia: a propensity score-matched analysis
por: Kwag, Daehun, et al.
Publicado: (2022)

Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report
por: Wang, Lei, et al.
Publicado: (2021)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Venetoclax in Previously Treated Waldenström Macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2022)

Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax
por: Izutsu, Koji, et al.
Publicado: (2023)

P622: GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS
por: Yosifov, Deyan, et al.
Publicado: (2023)

Lysosomal Machinery Drives Extracellular Acidification to Direct Non-apoptotic Cell Death
por: Mondragon, Albert A., et al.
Publicado: (2019)

A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
por: Borthakur, Gautam, et al.
Publicado: (2021)

Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia
por: Kornauth, Christoph, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i3gq6g37mspcj5q14tfcno77ve